Company Profile

Surfagen Inc
Profile last edited on: 12/18/19      CAGE: 4WY93      UEI:

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
2007
First Award
2009
Latest Award
2009
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

475A East Bay Street
Charleston, SC 29403
   (843) 276-1533
   N/A
   www.surfagen.com
Location: Single
Congr. District: 06
County: Charleston

Public Profile

Surfagen is focused on the development of novel nanoparticle systems for the delivery of siRNA therapeutics. siRNA therapeutics, a recently developed approach for treating major diseases, has created a great deal of excitement because of its potential to impact the genes responsible for a wide variety of medical problems. As a result, a great deal of money has been invested, both by major pharmaceutical companies and private investors, in new companies that are developing siRNA therapeutics. However, one problem that has prevented siRNA from reaching its potential is the lack of a good delivery system. Surfagen , Inc. is developing a new class of novel multifunctional carriers (MFCs) that overcome the deficiencies of delivery systems for siRNA therapeutics being used by other companies.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2009 1 NIH $137,575
Project Title: Multifunctional Carriers for Systemic Sirna Delivery

Key People / Management

  Steven Brostoff -- Chairman and CEO

  Tom Finnegan -- President, COO and CFO

  Zheng-Rong Lu -- founder

Company News

There are no news available.